Browsing Tag
DVAX
1 post
Dynavax (NASDAQ: DVAX) targets 60% U.S. hepatitis B market share by 2030 amid COVID vaccine deal, $100m buyback
Dynavax targets 60% of U.S. hepatitis B vaccine market by 2030, expands COVID-19 pipeline, and authorizes $100M buyback. Read what this signals for investors.
November 6, 2025